Cycle Trading: Watching for a Biotech Breakout
|Biotech's 2.41% gain on Monday rekindled my interest in this sector.
Biotech had a great multi-year run peaking in July, 2015. It went on to print its mutli-year low in February of 2016. And since then it has been consolidating below the 300 level.
A closer look reveals that Biotech has recently had multiple tests of the 300 level.
Notice how the 50 week MA is now aligned with the 200 week MA.
Since the last test of the 300 level was launched from support from the convergence of both the 50 week MA & the 200 week MA, a clear and convincing close above the 300 level should break Biotech out of its 16 month consolidation.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.